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Aims To assess the international validity of using hospital record data to compare long-term outcomes in heart attack
survivors.
Methods
and results
We used samples of national, ongoing, unselected record sources to assess three outcomes: cause death; a composite
of myocardial infarction (MI), stroke, and all-cause death; and hospitalized bleeding. Patients aged 65 years and older
entered the study 1 year following the most recent discharge for acute MI in 2002–11 [n ¼ 54 841 (Sweden), 53 909
(USA), 4653 (England), and 961 (France)]. Across each of the four countries, we found consistent associations with 12
baseline prognostic factors and each of the three outcomes. In each country, we observed high 3-year crude cumulative
risks of all-cause death (from 19.6% [England] to 30.2% [USA]); the composite of MI, stroke, or death [from 26.0%
(France) to 36.2% (USA)]; and hospitalized bleeding [from 3.1% (France) to 5.3% (USA)]. After adjustments for baseline
risk factors, risks were similar across all countries [relative risks (RRs) compared with Sweden not statistically signifi-
cant], but higher in the USA for all-cause death [RR USA vs. Sweden, 1.14 (95% confidence interval 1.04–1.26)] and
hospitalized bleeding [RR USA vs. Sweden, 1.54 (1.21–1.96)].
Conclusion The validity of using hospital record data is supported by the consistency of estimates across four countries of a high
adjusted risk of death, further MI, and stroke in the chronic phase after MI. The possibility that adjusted risks of mortality
and bleeding are higher in the USA warrants further study.
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Introduction
Health records from different health systems might provide insights
into the care of patients with chronic diseases and the long-term
outcomes of these conditions,1,2 but there have been few compar-
isons across countries. National hospital data are collected and
coded in health systems in many countries and such data (compared
with voluntary registries or consented studies) may provide samples
* Corresponding author. Tel: +44 2035495329, Fax: +44 2076798002, Email: h.hemingway@ucl.ac.uk
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
European Heart Journal – Quality of Care and Clinical Outcomes (2016) 2, 172–183
doi:10.1093/ehjqcco/qcw004
 by guest on Septem
ber 5, 2016
http://ehjqcco.oxfordjournals.org/
D
ow
nloaded from
 
that are larger, more nationally representative, and not limited to
the study of any one disease, or any one stage of its development.3
However, there are important concerns about the quality and valid-
ity of such data.
In coronary disease, most studies of outcomes following myocar-
dial infarction (MI) have focused on the acute phase post-MI, typic-
ally up to 1 year. However, given marked improvements over the
past decade in short-term and long-term mortality following MI,4–6
there is a growing need to characterize the outcomes experienced
by patients in whom follow-up begins after the acute phase.
By the time of the first anniversary following admission for an acute
MI, dual antiplatelet therapy,7 – 10 cardiac rehabilitation, and cardi-
ologist follow-up11 have commonly ended, and uptake of secondary
prevention medication may be declining.12 Recent clinical guide-
lines7 –10 do not directly address the care of patients in this chronic
phase of disease, whereas a recent trial found that prolonged dual
antiplatelet therapy beyond the first year after an acute MI lowers
the risk of cardiovascular death, MI, and stroke.13
To deliver better long-term care for patients surviving MI, two
central questions need addressing. First, what is the risk of major
clinical outcomes following the high-risk acute post-MI phase? Near-
ly all previous studies14,15 of MI outcomes start in the acute hospital
setting rather than in the community, and it is well known that early
events predominate in estimates of long-term risk. Most of the infor-
mation on long-term outcomes available so far is derived from trials
and voluntary registries, whose risks may not extrapolate to the
wider patient population.16 Secondly, how do long-term clinical
outcomes vary in different health systems? While international
comparisons of cancer outcomes17 have influenced policy and
quality-improvement initiatives, in coronary disease comparisons
have been limited to the acute hospital care setting.5,18,19
To answer these questions, we sought national, unselected, on-
going sources of data provided by the health systems in four coun-
tries. While these data sources have been used for acute MI
outcomes research within countries,20 their use in evaluations of
the chronic phase of disease has been much less common, and the
present study is the first to use such data to compare outcomes be-
tween the USA and European countries (Sweden, England, and
France). Our objective was to test the validity of using such hospital
record data to estimate and compare across countries the risk of
three prognostic outcomes among MI survivors: all-cause death; com-
posite of MI, stroke, or all-cause death; and hospitalized bleeding.
Methods
Health record data sources and study
population
We analysed anonymized patient data from national ongoing hospital
sources that use the International Classification of Diseases (ICD) cod-
ing system. In Sweden, we used nationwide (100% population coverage)
administrative linked data (not directly used for reimbursement)
obtained from mandatory Swedish national registries: the National
Inpatient Register, the Swedish Prescribed Drug Register, and the Cause
of Death Register. In the USA, we used an administrative claims database
(Medicare) obtained from the Centers for Medicare & Medicaid
Service’s standard analytic files that are publicly available; these contain
a nationally representative 5% random sample of all Medicare
beneficiaries, based on selecting records with 05, 20, 45, 70, or 95 in po-
sitions 8 and 9 of the Social Security Number (SSN) (Centers for
Medicaid and Medicare, Standard Analytical Files. https://www.cms.gov/
research-statistics-data-and-systems/files-for-order/limiteddatasets/
standardanalyticalfiles.html, accessed 17 December 2015). Patients are
linked across the enrolment and eligibility file and service claims files using
a unique encrypted SSN. Deaths are determined by linkage to the Nation-
al Death file. In England, a single primary care electronic health record
(EHR) covers.95% of the population and we used a 4% sample available
for research. We used the CALIBER research platform of primary care
EHRs (Clinical Practice Research Datalink), linked via the unique identifier
of the National Health Service number with other record sources
[the Myocardial Ischaemia National Audit Project (MINAP), the Hospital
Episodes Statistics database, and the nationwide cause-specific mortality
database]. The CALIBER data resource has been shown to be represen-
tative of the general population,21 – 23 and valid for cardiovascular re-
search.24 – 28 In France, the source data came from the administrative
claims insurance database, which covers 95% of the French population.
The sample [Echantillon Ge´ne´raliste des Be´ne´ficiaires (EGB)] available
for researchers was built by randomly selecting patients from their nation-
al id check number (97 random possibilities). This permanent 1/97 sample
has been shown to be representative in terms of age, sex, social status,
and overall medical expenses.29 – 33 The EGB health insurance claims
data are linked to hospital discharge summaries and death registry
through the unique healthcare identifier number.
Our study population was defined by the presence of three charac-
teristics. First, we identified an index acute MI as the patient being admit-
ted to hospital with a primary diagnosis of MI [ICD, Tenth Revision
(ICD-10): I21 (Sweden, England, France), I22 (England, France); ICD,
Ninth Revision, Clinical Modification (ICD-9-CM): 410.x (excluding
410.x2) (USA)] between 2005 and 2009 (England), 2005 and 2010
(France), 2006 and 2011 (Sweden), and 2002 and 2009 (USA). Where
data permitted (England and the USA), the index MI was classified as
ST-elevation MI (STEMI) or non-STEMI (NSTEMI) based on MI registry
diagnoses (England) or by ICD-9-CM codes (STEMI, 410.0–410.6,
410.8; NSTEMI, 410.7) (USA).34 Patients had to have continuous regis-
tration in the respective data sets for at least 12 months before the index
MI (the first MI admission during the study period). Second, we identi-
fied those patients who at 12 months after their index acute MI were
alive, with no further MI. We defined the study entry date as 12 months
after the date of admission for the index MI. Third, we restricted the
population to patients aged 65 years and older at study entry with no
upper age bound, because Medicare predominantly covers this age
group (the USA has no national unselected sources of data in younger
patients).
The study was approved by the Independent Scientific Advisory
Committee of the Medicines and Healthcare products Regulatory
Agency (protocol number 13_163) in England, regional ethics commit-
tee in Linko¨ping, Sweden (reference number 2013/294-31), and Centers
for Medicare & Medicaid Services Data Use Agreement in the USA. No
ethical approval is required in France for the use of anonymized data.
Baseline risk factors and co-morbidities
We included demographics (age, sex) and cardiovascular and non-
cardiovascular co-morbidities (ICD-9 and ICD-10 codes in Supplementary
material online, Table S1) appearing as primary or secondary diagnoses in
hospital admissions before the study entry date. We considered patients as
currently receiving a medication (codes in Supplementary material online,
Table S2) if their last active prescription or dispensation ended ,60 days
before study entry. No prescription data were available in the Medicare
data. We included percutaneous coronary intervention (PCI) and
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coronary artery bypass graft (CABG) procedures performed on the day of
the index MI up to the following 12 months.
Endpoints
We studied three outcomes of interest: all-cause death; a composite of
death, hospital admission for MI, or hospital admission for stroke; and
hospitalized bleeding. The ICD-9/ICD-10 codes used to define these
outcomes are shown in Supplementary material online, Table S3. Stroke
types included ischaemic, haemorrhagic, and unclassified. Hospitalized
bleeding was defined as hospital admission with a bleeding cause as a
primary diagnosis. Patients were censored at the earliest of experiencing
the event of interest (with censoring specific to that event type),
deregistration from the primary care practice (England), or end of
study period.
Statistics
Data from each of the four countries were analysed independently
following a common protocol. We estimated the direct age- and
sex-standardized prevalence of co-morbidities in each country using
as reference the 2012 World Health Organization world population
truncated to ages 65 years and older. For each country and endpoint,
we estimated observed (Kaplan–Meier) and predicted risks, adjusted
to the average characteristics of the Swedish patients (aged 78 years,
with covariate values shown in Supplementary material online,
Table S4). We chose Sweden as the reference population because it
had the largest sample size. Predicted risks were based on incrementally
adjusted Cox models (fitted separately per country): Model 1 included
age, sex, and year of index MI; Model 2 included Model 1 covariates plus
co-morbidities [history of more than one MI, diabetes, renal disease,
heart failure, peripheral arterial disease (PAD), atrial fibrillation, stroke,
hospitalized bleeding, chronic obstructive pulmonary disease, and can-
cer]; Model 3 included Model 2 covariates plus revascularization proce-
dures (CABG or PCI) received in the 12 months following the index
MI. Annual risks were estimated as the average annual risks over the first
3 years.
We estimated the relative risks (RRs) for each endpoint in each
country and the 95% confidence intervals (CIs) for 3 years of
follow-up using as reference the corresponding risks estimated for
Sweden. For a time point t the RR for country A vs. country B is
RR t = (risk(t) A)/(risk(t) B). The overall RR reported is the mean of
RR t {t = 0, 0.5, . . . 3 years}. We verified the proportional hazards as-
sumption of the Cox model within countries by plotting the Schoenfeld
residuals and confirmed that RRs did not change with time by plotting
time-specific RRs estimated for every half year between 0 and 3 years
of follow-up (Supplementary material online, Figure S5).
We compared the associations of age, sex, co-morbidities, and re-
vascularization treatments with the outcomes across the different coun-
tries based on the adjusted hazard ratios (HRs) in Model 3. The overall
mean HR for a risk factor was estimated by combining country-specific
HRs via random-effects meta-analysis. For France, risk of hospitalized
bleeding was adjusted only for Model 1, owing to the small number of
events (n ¼ 23). Analyses were performed in R version 15 and SAS
version 9.3.
Results
Patients
Of the 220 738 patients hospitalized for MI during the study period,
114 364 (54 841 in Sweden, 53 909 in the USA, 4653 in England, and
961 in France) were eligible for inclusion in the analysis (alive, aged
65 years and older, and without subsequent MI at 12-month follow-
up; Supplementary material online, Figure S1). Median follow-up ran-
ged from 1.5 years (England) to 3.2 years (USA), during which a total
of 37 626 deaths, 45 072 events of MI/stroke/death, and 4697 bleed-
ing hospitalizations were observed in the four countries.
Baseline characteristics
Baseline characteristics of the post-MI survivors from each country
are shown in Table 1. Mean age ranged from 77.5 years in England to
78.6 years in the USA. After standardization for age and sex, we
found that compared with patients from Sweden, England, and
France, US patients had a higher prevalence of diabetes, heart fail-
ure, PAD, renal disease, and chronic obstructive pulmonary disease,
and were more likely to have undergone CABG (Figure 1).
All-cause death
There were large differences in the unadjusted (Kaplan–Meier) risk
of all-cause death across the four countries (Figure 2). Event rates
remained high throughout follow-up, with fairly constant risks per
year. The 3-year cumulative risk of death was lowest in England
[19.6% (95% CI, 18.0–21.2)] and France [22.1% (19.3–24.9)],
higher in Sweden [26.9% (26.5–27.4)], and highest in the USA
[30.2% (29.8–30.7)]. These differences were progressively attenu-
ated to not statistically significant (95% CI for the RR vs. Sweden
crossing 1) after sequential adjustments for age, sex, year of index
MI, co-morbidities, and revascularization treatments, except for
the USA where the RR of death compared with Sweden was slightly
higher [RR USA vs. Sweden, 1.14 (95% CI, 1.04–1.26)]. Based on
the mean covariates in the Swedish sample as per Table 1, the fully
adjusted 3-year cumulative risks ranged from 12.8% (England) to
19.5% (USA).
Myocardial infarction, stroke,
and all-cause death
There were large differences in the unadjusted (Kaplan–Meier) risk
of the composite endpoint MI, stroke, or death across the four
countries (Figure 3). Event rates remained high throughout follow-
up, with fairly constant risks per year. The lowest risk was observed
in France [26.0% (95% CI, 23.0–29.0)] and the highest in the USA
[36.2% (95% CI, 35.7–36.6)]; risks were similar in Sweden [34.3%
(95% CI, 33.8–34.7)] and England [32.5% (95% CI, 30.6–34.4)].
After adjustments, the risk of MI/stroke/death was similar across
all four countries (RRs vs. Sweden were not statistically significant).
Based on the mean covariates in the Swedish sample as per Table 1,
the fully adjusted 3-year cumulative risk of MI, stroke, or death ran-
ged from 24.4% (France) to 28.9% (England).
The proportion of deaths attributed to cardiovascular disease
(CVD) was 57.9% (8309/14 341) in Sweden and 46.7% (280/599)
in England. English patients had lower observed risks for MI, stroke,
or CVD death [23.0% (95% CI, 21.3–24.8)] than Swedish patients
[26.1% (95% CI, 25.7–26.5)], but a similar risk after adjustment
for age, co-morbidities, and revascularization treatments [RR 0.94
(95% CI, 0.77–1.13)] (Supplementary material online, Figure S2).
Hospitalized bleeding
The observed 3-year cumulative risk of hospitalized bleeding was
lowest in France (3.1%) and Sweden (3.2%), higher in England
(4.6%), and highest in the USA (5.3%) (Figure 4). The adjusted
E. Rapsomaniki et al.174
 by guest on Septem
ber 5, 2016
http://ehjqcco.oxfordjournals.org/
D
ow
nloaded from
 
3-year risk of hospitalized bleeding ranged from 2.7% (Sweden) to
4.0% (USA and England). Compared with Sweden, the fully adjusted
RR of bleeding for French and English patients was close to 1.0
(not statistically significant), but was .50% higher for US patients
[RR 1.54 (95% CI, 1.21–1.96)].
Outcome predictors
Each of the three outcomes showed consistent and strong (majority
of HRs .1.5) age- and sex-adjusted associations across the four
countries for 12 baseline variables assessed, including risk factors
and cardiovascular and non-cardiovascular co-morbidities. The
strongest associations (approximately two-fold increase in risk)
with the composite of MI, stroke, or death (Figure 5) or with all-
cause death alone (Supplementary material online, Figure S3) were
observed for history of renal disease, heart failure, chronic obstruct-
ive pulmonary disease, and cancer. For hospitalized bleeding, the
strongest associations were observed with history of previous
hospitalized bleeding, renal disease, heart disease, PAD, and atrial
fibrillation (Supplementary material online, Figure S4).
Discussion
In one of the first US–European uses of hospital record data to
evaluate long-term fatal and non-fatal clinical outcomes in CVD,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics for 114 364 myocardial infarction survivors aged 65 years and older in four countries
Sweden USA England France
Index MI, n 80 327 99 343 6653 1308
MI survivor study population, n (%) 54 841 (68.3) 53 909 (54.3) 4653 (70.0) 961 (73.5)
Follow-up, years, median (IQR) 2.4 (1.2–3.8) 3.2 (1.6–5.3) 1.5 (0.7–2.5) 3.0 (1.7–3.0)
Demographics
Women, n (%) 23 280 (42.4) 26 524 (49.2) 1933 (41.5) 422 (43.9)
Mean age, years (SD) 78.0 (8.0) 78.6 (7.5) 77.5 (7.7) 77.6 (7.3)
White ethnicity, n (%) Not recorded 48 044 (89.1) 3679 (94.6) Not recorded
NSTEMI (index MI), n (%) Not recorded 34 576 (64.1) 2393 (51.4) Not recorded
Mean BMI, kg/m2 (SD) 27.5 (4.8)a Not recorded 27.3 (5.0) Not recorded
Current smoking, n (%) Not recorded Not recorded 444 (10.3) Not recorded
Co-morbidities and medical history, n (%)
Diabetesa 13 351 (24.3) 18 907 (35.1) 1087 (23.4) 256 (26.6)
.1 MI 8786 (16.0) 6465 (12.0) 651 (14.0) 129 (13.4)
Heart failure 18 170 (33.1) 24 283 (45.0) 1245 (26.8) 319 (33.2)
Cancer 7892 (14.4) 4508 (8.4) 499 (6.9) 167 (17.4)
Atrial fibrillation 13 931 (25.4) 15 215 (28.2) 1152 (24.8) 200 (20.8)
Hypertension 34 689 (63.3) 42 981 (79.7) 3246 (69.8) 663 (69.0)
Stroke 7156 (13.0) 3695 (6.9) 436 (9.4) 45 (4.7)
PAD 2230 (4.1) 5460 (10.1) 353 (7.6) 4 (0.4)
COPD 5478 (10.0) 14 859 (27.6) 556 (11.9) 116 (12.1)
Renal disease 3343 (6.1) 1809 (3.4) 452 (9.7) 99 (10.3)
Dementia 2291 (4.2) 1156 (2.1) 110 (2.4) 49 (5.1)
Previous hospitalized bleeding 5528 (10.1) 9159 (17.0) 398 (8.6) 41 (4.3)
Medication use,b n (%)
Aspirin 44 645 (81.4) Not recorded 3606 (77.5) 723 (75.2)
ADP-receptor blocker 12 741 (23.2) Not recorded 2357 (50.7) 597 (62.1)
Dual antiplatelet 10 932 (19.9) Not recorded 1832 (39.4) 469 (48.8)
Statin 38 144 (69.6) Not recorded 3942 (84.7) 729 (75.9)
b-blocker 43 913 (80.1) Not recorded 3078 (66.2) 687 (71.5)
ACEIs/ARBs 37 317 (68.0) Not recorded 3594 (77.2) 667 (69.4)
Calcium channel blocker 12 032 (21.9) Not recorded 1017 (21.9) 198 (20.6)
Warfarin 5081 (9.3) Not recorded 408 (8.8) 107 (11.1)
Revascularization (1-year post-index MI), n (%)
CABG 6970 (12.7) 9134 (16.9) 474 (10.2) 59 (6.1)
PCI 26 656 (48.6) 23 099 (42.9) 1519 (32.6) 562 (58.5)
ACEI, angiotensin-converting enzyme inhibitor; ADP, adenosine diphosphate; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft;
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PAD, peripheral
arterial disease; PCI, percutaneous coronary intervention; SD, standard deviation.
aBased on medications (UK, France, Sweden) or diagnosis in primary (UK) or secondary care (UK, Sweden, USA).
bRecorded prescription/dispensing or most recent prescription ending ,60 days before study entry.
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Figure 1 Age- and sex-standardized prevalence of co-morbidities and secondary prevention treatments in post- myocardial infarction survivors
aged 65 years and older. Estimates correspond to the direct age- and sex-standardized prevalence of co-morbidities in each country using as ref-
erence the 2012 World Health Organization world population truncated to age 65 years and older. ACEI, angiotensin-converting enzyme inhibi-
tor; ADP, adenosine diphosphate; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary
disease; CVD, cardiovascular disease; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention.
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we present two findings that suggest that such data have useful val-
idity and are informative in CVD outcomes research.
First, there was a consistency across all four countries in the high
level of risk of further MI, stroke, or death. This occurred in about a
third of the patients aged 65 years and above over the next 3 years.
This suggests that the high risk is an international phenomenon, ra-
ther than a problem with one healthcare system or resulting from
the different natures of the underlying record systems. This high
risk was considerably higher than that reported in the few smaller
previous studies conducted in selected populations,16 highlighting
the value of examining less-selected patient samples.
Second, there was a consistency across all four countries in the
magnitudes of association between 12 baseline risk factors and
each of the three disease outcomes. These associations were highly
consistent with published findings from smaller, consented studies,
supporting the validity of our risk adjustment and comparison of
outcomes. Thus, as in previous studies in post-MI survivors,35 – 37
we found strong associations between MI, stroke, or death (with
heart failure, stroke, PAD, diabetes, renal disease, and chronic ob-
structive pulmonary disease) and for hospitalized bleeding (with re-
nal disease, history of hospitalized bleeding, and atrial fibrillation).
This provides some evidence of the prognostic validity of the hos-
pital record data coded in different healthcare systems, despite
the diversity of data collection systems.
Our approach was to use hospital healthcare records that have
features of ‘big data’: being characterized by large sample sizes
(‘volume’), diverse data sources, collected for different purposes,
and using different coding systems (‘variety’) and lack of researcher
control over the meaning of the data (‘veracity’). This approach has
been widely advocated in understanding and improving the
Figure 2 Risks of all-cause death in post-myocardial infarction survivors aged 65 years and older followed from 1 year after the index myocardial
infarction. Observed (Kaplan–Meier) risks (top left), adjusted risks (top right), and relative risks vs. Sweden (bottom) in post-myocardial infarction
survivors from Sweden (n ¼ 54 841), USA (n ¼ 53 909), England (n ¼ 4653), and France (n ¼ 961). CABG, coronary artery bypass graft; CI, con-
fidence interval; KM, Kaplan–Meier; PCI, percutaneous coronary intervention; RR, relative risk.
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outcomes of disease,1 but seldom applied in international con-
texts.38 The strengths of this approach (compared with voluntary
registries or consented studies) lie in direct health system relevance,
less bias (larger samples, unselected population-based samples,
long-term follow-up with minimal losses), and potential scalability
to a wide range of clinical start points and endpoints.3 Such record
data are also more widely accessible to the research community
than those from consented studies.
Our study has important limitations, which are largely inherent in
these diverse data sources. First, in only one country (Sweden) were
nationwide data accessed; the sample of national data available for
research in France was particularly small, but it is, nonetheless, rep-
resentative of the French population. Second, such health record
data will inevitably lack relevant data items. For example, MI subtype
(STEMI or NSTEMI) was not recorded across all four countries and
could not therefore be included in the model adjustments. How-
ever, there is strong evidence that, at 1 year following the index
MI, STEMI and NSTEMI shared similar mortality, suggesting that
MI subclass is unlikely to have influenced our comparisons.39 Infor-
mation on younger patients, socioeconomic position, ethnicity, drug
use, primary care, and cause-specific death was not simultaneously
available in all four countries. It is a challenge to these health systems
to improve the coverage, depth, and quality of data as part of efforts
to expand international comparisons.
We observed an annual risk of death ranging from 6.5% (England)
to 10.0% (USA), more than double those in the general population
Figure 3 Risks of the composite of myocardial infarction, stroke, and all-cause death in post-myocardial infarction survivors aged 65 years and
older followed from 1 year after the index myocardial infarction. Observed (Kaplan–Meier) risks (top left), adjusted risks (top right), and relative
risks vs. Sweden (bottom) in post-myocardial infarction survivors from Sweden (n ¼ 54 841), USA (n ¼ 53 909), England (n ¼ 4653), and France
(n ¼ 961). CABG, coronary artery bypass graft; CI, confidence interval; KM, Kaplan–Meier; PCI, percutaneous coronary intervention; RR, relative
risk.
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[ranging from 2.9% (France) to 3.7% (UK and USA) in age group 75–
79 years] (Supplementary material online, Table S5). Since 57.9% of
deaths are due to CVD (based on Swedish data), our study popula-
tion is in the high-risk category based on the 2012 American College
of Cardiology/American Heart Association guidelines (where high
risk is defined as .3% annual risk of cardiovascular death)40 or
the 2013 European Society of Cardiology guidelines (where high
risk is defined as .3% annual risk of all-cause death).41 However,
these guidelines are described in the context of the wider popula-
tion of patients with stable coronary artery disease (many of
whom have no history of MI). Also, most of the information comes
from meta-analyses of clinical trial data, in which survival is generally
higher owing to enrolment of lower-risk populations and better
adherence to therapy.
Our finding of higher adjusted death rates and hospitalized
bleeding rates in the USA than in Sweden could be artefactual
but warrants further investigation. The higher death rates are con-
sistent with the lower life expectancy at age 65 years in the USA
compared with Europe (Supplementary material online, Table
S5).42 It is possible that the case mix of patients differs in ways
that were not included in our adjustments (e.g. related to the sub-
stantially higher prevalence of obesity in the general US popula-
tion).42 We did find that US patients had higher age- and
sex-standardized prevalences of diabetes, heart failure, PAD, renal
disease, and chronic obstructive pulmonary disease—but each of
these factors was included in the risk adjustment models. The
USA might also have a higher proportion of ethnic minorities,
which could confound between-country comparisons. It is also
Figure 4 Risks of hospitalized bleeding events in post-myocardial infarction survivors aged 65 years and older followed from 1 year after the
index myocardial infarction. Observed (Kaplan–Meier) risks (top left), adjusted risks (top right), and relative risks (bottom) for hospitalized bleed-
ing events among post-myocardial infarction survivors from Sweden (n ¼ 54 841), USA (n ¼ 53 909), England (n ¼ 4653), and France (n ¼ 961).
CABG, coronary artery bypass graft; CI, confidence interval; KM, Kaplan–Meier; PCI, percutaneous coronary intervention; RR, relative risk.
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possible that care differs. Studies in the USA indicate that previous-
ly uninsured populations may delay seeking care before becoming
eligible for Medicare,43,44 and mortality may remain elevated for up
to 10 years, compared with those with private insurance.45 In con-
trast, European Union study populations would have had continu-
ous access to healthcare before the age of 65 years.46 It is possible
that in the USA compared with Europe secondary prevention
medications including dual antiplatelet therapy (aspirin and clopi-
dogrel) are used more or at higher doses;47 however, evidence
of this in unselected populations of MI survivors is lacking.
Reported use of other CVD medications in Medicare populations
indicates that treatment rates are similar to those observed in the
EU study population for b-blockers and calcium channel blockers,
but somewhat lower for angiotensin-converting enzyme inhibitors
and lipid-lowering therapies.48 – 53
Our findings have clinical implications. First, our results provide
evidence for clinicians and regulators when considering new inter-
ventions, and when assessing the generalizability of results from
clinical trials.13,43 The recently reported PEGASUS-TIMI-54 trial
results in 1-year MI survivors are the first to demonstrate a role
for long-term (i.e. beyond 1 year) dual antiplatelet use.13 We applied
the trial inclusion and exclusion criteria to our real-world patients
(Supplementary material online, Figure S1) and demonstrated that
the ‘trial-like’ population represents a large proportion (e.g. 66%
in Sweden) of the overall MI survivor population, and identified a
population at high risk (Supplementary material online, Figure S6).
Second, our findings suggest the value of considering MI in a chronic-
disease management framework, e.g. with a 1-year health check
after acute MI optimizing behavioural, secondary preventive, and
wider health interventions. We found that a substantial proportion
of deaths are from non-cardiovascular causes (53% in England and
42% in Sweden), suggesting the importance of a multidisciplinary
team approach in primary care. Guidelines need to be developed
for this population that recognize the multitude of cardiovascular
co-morbidities (atrial fibrillation, heart failure, diabetes, and PAD)
and non-cardiovascular co-morbidities (renal disease, chronic ob-
structive pulmonary disease) that are highly prevalent among long-
term survivors of MI.
Figure 5 Age- and sex-adjusted hazard ratios (95% confidence interval) for the association of age, sex, and medical history with the composite
of myocardial infarction, stroke, and all-cause death among post-myocardial infarction survivors from Sweden (n ¼ 54 841), USA (n ¼ 53 909),
England (n ¼ 4653), and Francea (n ¼ 961). aIncidence of PAD in the French study was ,0.5%; hence, it was not possible to obtain estimates of
association with outcomes. CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; MI, myocardial infarction;
PAD, peripheral arterial disease.
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In conclusion, analysing hospital record data in the USA and three
European countries reveals a consistently high adjusted risk of
death, further MI, and stroke in the chronic phase after MI. Inherent-
ly, diverse data produced by different health systems may provide
insights that are useful in evaluating and comparing the care of pa-
tients with chronic diseases and the long-term outcomes of these
conditions.
Supplementary material
Supplementary material is available at European Heart Journal – Quality
of Care and Clinical Outcomes online.
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